About the Authors
- Caterina Vacchi-Suzzi
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Florian Hahne
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Philippe Scheubel
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Magali Marcellin
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Valerie Dubost
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Magdalena Westphal
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Catherine Boeglen
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Stine Büchmann-Møller
-
Affiliation Biomarker Development, Novartis Institute for Biomedical Research, Basel, Switzerland
- Ming Sin Cheung
-
Affiliation Biomarker Development, Novartis Institute for Biomedical Research, Basel, Switzerland
- André Cordier
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Christopher De Benedetto
-
Affiliation Preclinical Safety, Novartis Institute of Biomedical Research, East Hanover, New Jersey, United States of America
- Mark Deurinck
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Moritz Frei
-
Affiliation Biomarker Development, Novartis Institute for Biomedical Research, Basel, Switzerland
- Pierre Moulin
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Edward Oakeley
-
Affiliation Biomarker Development, Novartis Institute for Biomedical Research, Basel, Switzerland
- Olivier Grenet
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Armelle Grevot
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Robert Stull
-
Affiliation Preclinical Safety, Novartis Institute of Biomedical Research, East Hanover, New Jersey, United States of America
- Diethilde Theil
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Jonathan G. Moggs
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Estelle Marrer
-
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
- Philippe Couttet
-
* E-mail: philippe.couttet@novartis.com
Affiliation Preclinical Safety, Novartis Institutes of Biomedical Research, Basel, Switzerland
Competing Interests
All authors are employees of the Novartis Pharma AG. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: CVS EM PC. Performed the experiments: CVS MM VD MW PS CDB MF CB. Analyzed the data: CVS FH MSC AC. Contributed reagents/materials/analysis tools: SBM EO RS AG. Wrote the paper: CVS PC EM. Supervised the study and experimental design: PC PM AC DT MD OG JGM. Reviewed and commented the manuscript: JGM.